Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GM2 ganglioside is a sialic acid-containing glycosphingolipid primarily located within the outer leaflet of neuronal plasma membranes, where it plays critical roles in cell signaling and membrane organization (PubChem CID 9835556). Under normal physiological conditions, it is catabolized in the lysosome by the enzyme Beta-hexosaminidase A (Hex A) in conjunction with the GM2 activator protein (UniProt P06865). In individuals with genetic deficiencies in Hex A (Tay-Sachs disease) or the activator protein (AB variant), GM2 ganglioside and related substrates like GA2 accumulate to toxic levels within lysosomes, leading to progressive neurodegeneration and central nervous system dysfunction (NIH GARD). Therapeutic strategies targeting this molecule focus on reducing its synthesis through substrate reduction therapy (SRT) or enhancing its degradation via enzyme replacement therapy (ERT), gene therapy, or pharmacological chaperones. Current drug development efforts, such as those involving venglustat, aim to cross the blood-brain barrier to mitigate the catastrophic neurological impact of GM2 accumulation.
Substrate reduction therapy (SRT) via inhibition of glucosylceramide synthase to decrease GM2 synthesis; Pharmacological chaperone therapy to stabilize mutant Beta-hexosaminidase A; Gene therapy or enzyme replacement to restore lysosomal degradation of GM2.
4 more in the full profile.
Source types: Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GM2 ganglioside (GM2).